Assessing gastro-intestinal related quality of life in cystic fibrosis: Validation of PedsQL GI in children and their parents
Open Access
- 20 December 2019
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (12) , e0225004
Abstract
Most patients with cystic fibrosis (CF) suffer from pancreatic insufficiency, leading to fat malabsorption, malnutrition and abdominal discomfort. Until recently, no specific tool was available for assessing gastro-intestinal related quality of life (GI QOL) in patients with CF. As the Horizon2020 project MyCyFAPP aims to improve GI QOL by using a newly designed mobile application, a sensitive and reliable outcome measure was needed. We aimed to study the applicability of the existing child-specific Pediatric Quality of Life Inventory, Gastrointestinal Symptoms Scales and Module (PedsQL GI) in children with CF. A multicenter, prospective observational study was performed in 6 European centers to validate the PedsQL GI in children with CF during 3 months. In total, 248 children and their parents were included. Within-patient variability of PedsQL GI was low (24.11), and there was reasonable agreement between children and parents (ICC 0.681). Nine of 14 subscales were informative (no ceiling effect). The PedsQL GI and the median scores for 4 subscales were significantly lower in patients compared to healthy controls. Positive associations were found between PedsQL GI and age (OR = 1.044, p = 0.004) and between PedsQL GI and BMI z-score (OR = 1.127, p = 0.036). PedsQL GI correlated with most CFQ-R subscales (r 0.268 to 0.623) and with a Visual Analogue Scale (r = 0.20). PedsQL GI is a valid and applicable instrument to assess GI QOL in children with CF. Future research efforts should examine the responsiveness of the CF PedsQL GI to change in the context of clinical interventions and trials.Keywords
Funding Information
- Horizon 2020 Framework Programme (643806)
This publication has 32 references indexed in Scilit:
- A first approach for an evidence-based in vitro digestion method to adjust pancreatic enzyme replacement therapy in cystic fibrosisPLOS ONE, 2019
- Pancreatic insufficiency in Cystic FibrosisJournal of Cystic Fibrosis, 2017
- Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findingsPLOS ONE, 2017
- Innovative approach for self-management and social welfare of children with cystic fibrosis in Europe: development, validation and implementation of an mHealth tool (MyCyFAPP)BMJ Open, 2017
- Pancreatic enzyme replacement therapy in cystic fibrosis: dose, variability and coefficient of fat absorptionRevista Española de Enfermedades Digestivas, 2017
- ESPEN-ESPGHAN-ECFS guidelines on nutrition care for infants, children, and adults with cystic fibrosisClinical Nutrition, 2016
- European Cystic Fibrosis Society Standards of Care: Best Practice guidelinesJournal of Cystic Fibrosis, 2014
- Factors associated with FEV1decline in cystic fibrosis: analysis of the ECFS Patient RegistryEuropean Respiratory Journal, 2013
- Longitudinal trends in nutritional status and the relation between lung function and BMI in cystic fibrosis: a population-based cohort studyThe American Journal of Clinical Nutrition, 2013
- Enzyme replacement therapy for pancreatic insufficiency: present and futureClinical and Experimental Gastroenterology, 2011